WednesdayAug 03, 2022 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership…

Continue Reading

WednesdayAug 03, 2022 10:49 am

Research Finds That Tourism, Travel May Boost Mental Health

A new study has suggested that tourism should be viewed as an industry that offers real health benefits, in addition to being viewed as a recreational experience. The study, which was conducted by researchers at the Center for Precision Health at the Edith Cowan University in collaboration with the School of Business and Law, discovered that various aspects of being on holiday could have a positive influence on individuals with mental health conditions. Dr. Jun Wen, the study’s lead researcher, stated that the diverse team of experts on public health, tourism and marketing looked into how tourism could benefit individuals…

Continue Reading

TuesdayAug 02, 2022 1:00 pm

Study Finds That Difficulty Sleeping, Financial Stressors Increase Mental Health Risk in University Students

New research on student well-being in the pandemic period has identified sleep difficulties and worsened financial situation as indicators of people with a heightened risk of developing mental health conditions. The findings, which were reported in the “BJPsychOpen” journal, will be useful to institutions of higher learning because they can help identify students with a high risk of developing mental health conditions and offer enhanced support to those students. For their study, researchers at the University of Warwick carried out a survey of more than 500 young adults who weren’t in higher education and almost 900 university students, between July…

Continue Reading

TuesdayAug 02, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system  Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants Every 9 minutes, a person is…

Continue Reading

TuesdayAug 02, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy CNS…

Continue Reading

MondayAug 01, 2022 11:15 am

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to age Odyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavity The PRV-002 drug is expected to offer reprieve to people suffering from concussion by potentially preventing long-term consequences of the condition The drug is currently undergoing evaluation as part of a Phase I study that has so far shown that it is well tolerated…

Continue Reading

MondayAug 01, 2022 9:47 am

Study Discovers Common Mechanism Behind Cancer Metastasis, Cardiovascular Disease

New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that involve interactions between the tumor and an individual’s immune system. While most of the details involved in this process are unclear, evidence has shown that endothelial cell inflammation plays a key role in a tumor’s progression to metastasis. Endothelial cells usually form a layer lining the blood vessels in the body, helping regulate exchanges between the bloodstream and surrounding tissue. The study objective of the researchers at Hokkaido University was to look…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050